Farhad Hafezi, M.D, Ph.D.

Farhad Hafezi, M.D, Ph.D.
Curriculum vitae
Academic degree:
Professor and Chair of Ophthalmology, University of Geneva, Switzerland
Clinical Professor of Ophthalmology, Doheny Eye Institute, USC, Los Angeles, USA
University Eye Clinic, Rue Alcide Jentzer 22, 1211 Geneva, Switzerland
November 1, 1967
Work address:
Date of birth:
Sixteen national and international awards, prizes and distinguished lectures in ophthalmology including the
2014 ARVO Foundation / Carl Camras Translational Research Award, the Jules Francois prize of the Belgian
Ophthalmological Society, highest award for ophthalmology in Belgium and the Alfred Vogt prize of the Swiss
Ophthalmological Society, highest award for ophthalmology in Switzerland. 1995 - present.
Innovation awards of the University of Geneva, of the Geneva University Hospitals and from VentureKick Stage 1
for a new cross-linking technology. 2013.
1994 - ongoing
Peer-reviewed primary publications, including "Nature Medicine" and "Nature Genetics":
Case reports, reviews and book chapters:
h -index:
Cumulative impact factor (ISI 2012):
Total cites:
> 3'200
Associate Editor
Journal of Refractive Surgery
Editorial Board Member
Translational Vision Science and Technology (TVST), Iranian Journal of Ophthalmology,
The International Journal of Keratoconus and Ectatic Corneal Disease
Hafezi F, Steinbach JP, Marti A, Munz K, Wang ZQ, Wagner EF, Aguzzi A, Reme CE. The absence
of c-fos prevents light-induced apoptotic cell death of photoreceptors in retinal
degeneration in vivo. Nat Med. 1997. 3(3): 346-9
Fleischmann A, Hafezi F, Elliott C, Reme CE, Ruther U, Wagner EF. Fra-1 replaces
c-Fos-dependent functions in mice. Genes Dev. 2000. 14(21): 2695-700
Grimm C, Wenzel A, Hafezi F, Yu S, Redmond TM, Reme CE. Protection of Rpe65-deficient mice
identifies rhodopsin as a mediator of light-induced retinal degeneration. Nat Genet. 2000.
25(1): 63-6
Hafezi F, Kanellopoulos J, Wiltfang R, Seiler T. Corneal collagen crosslinking with riboflavin and ultraviolet A to treat
induced keratectasia after laser in situ keratomileusis. J Cataract Refract Surg. 2007. 33(12): 2035-40
Iseli HP, Thiel MA, Hafezi F, Kampmeier J, Seiler T. Ultraviolet A/riboflavin corneal cross-linking for infectious keratitis
associated with corneal melts. Cornea. 2008. 27(5): 590-4
Hafezi F, Mrochen M, Iseli HP, Seiler T. Collagen crosslinking with ultraviolet-A and hypoosmolar riboflavin solution in thin
corneas. J Cataract Refract Surg. 2009. 35(4): 621-4
Hafezi F, Dejica P, Majo F. Modified corneal collagen crosslinking reduces corneal oedema and diurnal visual fluctuations in
Fuchs dystrophy. Br J Ophthalmol. 2010. 94(5): 660-1
Hafezi F, Koller T, Derhartunian V, Seiler T. Pregnancy may trigger late onset of keratectasia after LASIK. Journal of refractive
surgery. 2012. 28(4): 242-3
Richoz O, Schutz JS, Pajic B, Coskunseven E, Hafezi F. Crosslinking for recurrent keratoconus. Ophthalmology. 2012. 119(4):
878-78 e2
Richoz O, Mavrakanas N, Pajic B, Hafezi F. Corneal Collagen Cross-Linking for Ectasia after LASIK and Photorefractive
Keratectomy: Long-Term Results. Ophthalmology. 2013:
German (mother tongue). Fluent in english, french, polish (second mother tongue), persian
Farhad Hafezi completed his medical studies and medical doctorate in Switzerland in 1992. From 1993 to 1994, he attended a twoyear course in experimental medicine and biology at the ETH Zurich (nowadays MSc Biology), followed by three years as a scientific
post-doc in the Laboratory for Retinal Cell Biology in Zurich, Switzerland. Here, his research focused on molecular mechanisms of
retinal degeneration using light-induced photoreceptor damage in transgenic mice as an experimental model. He identifed he first
gene that would completely inhibit light-induced retinal damage (Hafezi et al., Nature Medicine, 1997).
Clinically, Prof. Hafezi focused on corneal and refractive laser surgery where he became a pioneer in the method of corneal collagen
cross-linking (CXL). He was instrumental in building a private institute in Zurich, Switzerland called IROC where the CXL technology
was clinically further developped and the UV-X device was constructed and CE certified. Based on IP generated in his team at the
University of Geneva, a spin-off company was launched in early 2013: EMAGine SA focuses on new modlaities to treat corneal infection. His PhD thesis from the Erasmus University of Rotterdam was on the management of complications in refractive laser surgery.
In 2010, Prof. Hafezi has been appointed Chair and Professor of Ophthalmology of the University Eye Clinic of Geneva in Switzerland.
In 2012, the Faculty of the Keck School of Medicine at the University of Southern California (USC) Los Angeles (Doheny Eye Institute)
has appointed Prof. Hafezi as Clinical Professor of Ophthalmology.
• International opinion leader in CXL, partner in the successful translation of CXL into clinical ophthalmology in 2002.
• Co-founded IROC together with Michael Mrochen and Theo Seiler. IROC is the institute in Zurich, Switzerland that developed the
first UV-X CXL device dominating the world market between 2003 and 2010.
• Has published > 40 scientific manuscripts on CXL
• Main author of the first descriptions of the use of modified CXL in iatrogenic keratectasia, in extremely thin corneas and in Fuchs
• Co-initiated the international CXL congress that was successfully held 7 times to date and he is the head of the organizing committee of the 8th international congress, that will be held in Geneva in December 2012.
• Founding member of the “Expert group on surgical options in the management of Keratoconus” of the European Society for Cataract and Refractive Surgery (ESCRS) and heads the CXL educational course of the ESCRS
• Board member for the CXL courses of the International Society for Refractive Surgery (ISRS) and American Academy of Ophthalmology (AAO)
• Editor of the textbook by Slack Inc "Corneal collagen cross-linking" (appeared in May 2013)